Paper of the Month
Paper of the month: Efficacy and safety of andexanet to reverse factor Xa inhibitors activity.
For February 2016 we have selected: Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;33:2413-2424.
There is an increased use of direct factor Xa inhibitors (like apixaban, rivaroxaban, and edoxaban) to prevent stroke in patients with nonvalvular atrial fibrillation since these medications have several advantages compared to vitamin K antagonists.